Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Moxalactam Disodium

FDA-approved product (injectable, injection), marketed as Moxam.

Registered studies
3
Lab records
1
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Moxalactam Disodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Third-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DD06

Repurposing investigation

Moxalactam Disodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli98.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae90.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • M. tuberculosis49.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

3registered studies name this medicine, for any condition. See them below.

Experimental

  • E. coli: measured active in 1 of 1 lab record
Open Moxalactam Disodium in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Moxalactam Disodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Antibiotic Therapy for Early Onset Neonatal Sepsis

    NCT03932123 · start 2019-05-05

    Registered record
    Registry ID
    NCT03932123
    Conditions
    Early Onset Neonatal Sepsis
    Interventions
    Piperacillin and tazobactam, azlocillin, latamoxef, meropenem, vancomycin，cefotaxime
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-05-05
    Completion
    2025-12
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly Onset Neonatal Sepsis
    InterventionPiperacillin and tazobactam, azlocillin, latamoxef, meropenem, vancomycin，cefotaxime
    PhaseNot recorded
    Registry statusUnknown

  • Population Pharmacokinetics of Cephalosporins and Macrolides in Chinese Children With Community Acquired Pneumonia

    NCT02775968 · start 2017-06-21

    Registered record
    Registry ID
    NCT02775968
    Conditions
    Community Acquired Pneumonia
    Interventions
    Cephalosporins and Macrolide Antibiotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2017-06-21
    Completion
    2022-10
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity Acquired Pneumonia
    InterventionCephalosporins and Macrolide Antibiotics
    PhaseNot recorded
    Registry statusUnknown

  • Population Pharmacokinetics of Anti-infective Drugs in Children With Infectious Diseases

    NCT03113344 · start 2017-06-21

    Registered record
    Registry ID
    NCT03113344
    Conditions
    Children; Infection
    Interventions
    cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2017-06-21
    Completion
    2025-12-31
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildren; Infection
    Interventioncephalosporins,penicillins,macrolides,carbapenems and antiviral drugs
    PhaseNot recorded
    Registry statusUnknown